The increasing frequency of mania and bipolar disorder: Causes and potential negative impacts

Journal of Nervous and Mental Disease

Volumn 200, Issue 5, 2012, Pages 380-387

  Yutzy, Sean H ^a   Woofter, Chad R ^b,c   Abbott, Christopher C ^d   Melhem, Imad M ^e   Parish, Brooke S ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Napa State Hospital   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e Neurobehavioral Medicine Consultants   (United States)

Author keywords

bipolar disorder(s); diagnostic errors; Mania; prevalence

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXYCARBAMAZEPINE; QUETIAPINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ZIPRASIDONE;

ALGORITHM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; DIAGNOSTIC ERROR; DRUG BLOOD LEVEL; DRUG INDUSTRY; DRUG OVERDOSE; DRUG SAFETY; DSM-III; FOLLOW UP; HUMAN; MAJOR AFFECTIVE DISORDER; MAJOR DEPRESSION; MANIA; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PROGNOSIS; REVIEW; SCHIZOPHRENIA; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ADVERTISING AS TOPIC; BIPOLAR DISORDER; DEPRESSION; DIAGNOSTIC ERRORS; DRUG INDUSTRY; HUMANS; INFORMED CONSENT; PREVALENCE; UNITED STATES;

EID: 84861065072     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0b013e3182531f17     Document Type: Review

References (142)

1. Akiskal HS (1996) The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol. 16:4S-14S.
2. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R (2000) Reevaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 59:S5-S30.
3. Akiskal HS, Mallya G (1987) Criteria for the 'soft' bipolar spectrum: Treatment implications. Psychopharmacol Bull. 23:68-73.
4. Akiskal HS, Pinto O (1999) The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am. 22:517-534, vii.
5. Alexander F, Selsnick S (1966) The history of psychiatry. New York, NY: Harper & Row
6. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
7. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
8. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Association.
9. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
10. American Psychiatric Association (2002a) American Psychiatric Association: Practice guideline for the treatment of depressive disorder (revision). Am J Psychiatry. 157:1-45.
11. American Psychiatric Association (2002b) Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 159:1-50.
12. Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther. 60:145-156.
13. Angst J (1998) The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 50:143-151.
14. Angst J, Ernst C (1993) Current concepts of the classification of affective disorders. Int Clin Psychopharmacol. 8:211-215.
15. Angst J, Marneros A (2001) Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect Disord. 67:3-19.
16. Applebaum P, Gutheil T (2007) Clinical handbook of psychiatry and the law. Philadelphia, PA: Lippincott Williams & Wilkins.
17. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L (2008) Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 59:1175-1183.
18. Baldessarini R, Tarazi F (Eds) (2005) Pharmacotherapy of psychosis in mania. New York, NY: McGraw-Hill.
19. Baldessarini RJ (2000) A plea for integrity of the bipolar disorder concept. Bipolar Disord. 2:3-7.
20. Baldessarini RJ, Pompili M, Tondo L (2006) Suicide in bipolar disorder: Risks and management. CNS Spectr. 11:465-471.
21. Baldessarini RJ, Tondo L (2000) Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry. 57:187-190.
22. Baldessarini RJ, Tondo L, Hennen J (1999) Treatment delays in bipolar disorders. Am J Psychiatry. 156:811-812.
23. Balestrieri M, Vampini C, Bellantuono C (2000) Efficacy and safety of novel antipsychotics: A critical review. Hum Psychopharmacol. 15:499-512.
24. Barbey JT, Roose SP (1998) SSRI safety in overdose. J Clin Psychiatry. 59:42-48.
25. Bauer MS, Mitchner L (2004) What is a 'mood stabilizer'? An evidence-based response. Am J Psychiatry. 161:3-18.
26. Beauchamp T, Childress J (2008) Priniciples of biomedical ethics. New York, NY: Oxford University Press.
27. Benazzi F (1997) Prevalence of bipolar II disorder in outpatient depression: A 203-case study in private practice. J Affect Disord. 43:163-166.
28. Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA (2003) Economic consequences of not recognizing bipolar disorder patients: A cross-sectional descriptive analysis. J Clin Psychiatry. 64:1201-1209.
29. Block AE (2007) Costs and benefits of direct-to-consumer advertising: The case of depression. Pharmacoeconomics. 25:511-521.
30. Body R, Foex B (2009) On the philosophy of diagnosis: is doing more good than harm better than 'primum non nocere'? Emerg Med J. 26:238-240.
31. Bond DJ, Pratoomsri W, Yatham LN (2007) Depot antipsychotic medications in bipolar disorder: A review of the literature. Acta Psychiatr Scand Suppl. (suppl 434):3-16.
32. Bowden CL (1998) New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology. 19:194-199.
33. Bowden CL (2001) Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv. 52:51-55.
34. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebocontrolled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 60:392-400.
35. Brim JA (1998) Overdiagnosis of major psychiatric disorders in individuals with substance use disorders and personality disorders: The downside of the Woodruff principle. J Stud Alcohol. 59:477-478.
36. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL (2009) 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila). 47:911-1084.
37. Burdick KE, Braga RJ, Goldberg JF, Malhotra AK (2007) Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs. 21:971-981.
38. Cade JF (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust. 2:349-352.
39. Cassano GB, Akiskal HS, Savino M, Musetti L, Perugi G (1992) Proposed subtypes of bipolar II and related disorders: With hypomanic episodes (or cyclothymia) and with hyperthymic temperament. J Affect Disord. 26:127-140.
40. Cassel CK (1996) The patient-physician covenant: An affirmation of Asklepios. Conn Med. 60:291-293.
41. Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 161:414-425.
42. Coryell W (1996) Bipolar II disorder: A progress report. J Affect Disord. 41:159-162.
43. Dunner DL (2005) Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord. 7:307-325.
44. Dunner DL, Gershon ES, Goodwin FK (1976) Heritable factors in the severity of affective illness. Biol Psychiatry. 11:31-42.
45. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E (2003) Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 160:112-117.
46. Farquhar F, Le Noury J, Tschinkel S, Harris M, Kurien R, Healy D (2007) The incidence and prevalence of manic-melancholic syndromes in North West Wales: 1875-2005. Acta Psychiatr Scand Suppl. (suppl 433):37-43.
47. Feighner J, Robins E, Guze S, Woodruff R, Winokur G, Munoz R (1973) Criteria for use in psychiatric research. Arch Gen Psychiatry. 26:57-63.
48. Gagrat D, Spiro H (1980) Social, cultural and epidemiological aspects of mania. New York, NY: Spectrum Publications.
49. Ghaemi S, Ko J (Eds) (2002) Polypharmacy of bipolar disorder. New York, NY: Marcel Dekker.
50. Ghaemi SN (2001) On defining 'mood stabilizer'. Bipolar Disord. 3:154-158.
51. Ghaemi SN, Boiman EE, Goodwin FK (2000) Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study. J Clin Psychiatry. 61:804-808; quiz, 809.
52. Ghaemi SN, Ko JY, Goodwin FK (2002) 'Cade's disease' and beyond: Misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry. 47:125-134.
53. Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH (2008) Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J Clin Psychiatry. 69:1751-1757.
54. Goodwin F, Jamison K (2007) Manic-depressive illness. New York, NY: Oxford University Press.
55. Goodwin GM (2009) Evidence-based guidelines for treating bipolar disorder: Revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 23:346-388.
56. Gutierrez-Rojas L, Jurado D, Gurpegui M (2011) Factors associated with work, social life and family life disability in bipolar disorder patients. Psychiatry Res. 186:254-260.
57. Hantouche EG, Akiskal HS, Lancrenon S, Allilaire JF, Sechter D, Azorin JM, Bourgeois M, Fraud JP, Chatenet-Duchene L (1998) Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord. 50:163-173.
58. Healy D (2006) The latest mania: selling bipolar disorder. PLoS Med. 3:e185.
59. Helzer JE, Kraemer HC, Krueger RF, Wittchen HU, Sirovatka PJ, Regier DA (2008) Dimensional Approaches in Diagnostic Classification: Refining the Research Agenda for DSM-V. Washington DC: American Psychiatric Association.
60. Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR Jr, Morrell MJ (2004) Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology. 63:1022-1026.
61. Hirschfeld RM (2001) Bipolar spectrum disorder: Improving its recognition and diagnosis. J Clin Psychiatry. 62:5-9.
62. Hirschfeld RM, Lewis L, Vornik LA (2003) Perceptions and impact of bipolar disorder: How far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 64:161-174.
63. Hirschfeld RM, Vornik LA (2004) Recognition and diagnosis of bipolar disorder. J Clin Psychiatry. 65:5-9.
64. Hutto B (2001) Potential overdiagnosis of bipolar disorder. Psychiatric services. 52:687-688.
65. IMS Health National Sales Perspectives (2011) Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/2008-Top-Therapy-Classes-by-U. S.-Sales.pdf. Accessed on January 5, 2011.
66. Johnson RE, McFarland BH (1996) Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 153:993-1000.
67. Jureidini J, Mintzes B, Raven M (2008) Does direct-to-consumer advertising of antidepressants lead to a net social benefit? Pharmacoeconomics. 26:557-566; discussion 567-558.
68. Justice, U. S. D.o. (2011a) Available at: http://www.justice.gov/opa/pr/ 2004/May/04-civ-322.html. Accessed on January 5, 2011.
69. Justice, U. S. D.o. (2011b) Available at: http://www.justice.gov/opa/pr/ 2007/Sept/07-civ-782.htm.
70. Justice, U. S. D.o. (2011c) Available at: http://www.justice.gov/opa/pr/ 2009/January/09-civ-038.html.
71. Justice, U. S. D.o. (2011d) Available at: http://www.justice.gov/usao/ma.
72. Justice, U. S. D.o. (2011e) Available at: http://www.justice.gov/usao/ pae/News/Pr/2010/Sept/Novartisentryofplea.pdf.
73. Katzow JJ, Hsu DJ, Ghaemi SN (2003) The bipolar spectrum: A clinical perspective. Bipolar Disord. 5:436-442.
74. Keck PE Jr, McElroy SL (2003) Redefining mood stabilization. J Affect Disord. 73:163-169.
75. Keck PE Jr, McElroy SL, Strakowski SM, Bourne ML, West SA (1997) Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull. 33:87-91.
76. Keller MB, Lavori PW, Kane JM, Gelenberg AJ, Rosenbaum JF, Walzer EA, Baker LA (1992a) Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry. 49:371-376.
77. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T (1992b) Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 49:809-816.
78. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 51:8-19.
79. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S (1997) The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med. 27:1079-1089.
80. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM (1999) Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol. 19:511-532.
81. Ketter TA, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, O'Keeffe CM, Schumacher MR (2005) Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry. 66:642-645.
82. Klerman GL (1981) The spectrum of mania. Compr Psychiatry. 22:11-20.
83. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P (2005) Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 293:1995-2002.
84. Kuehn BM (2010) Questionable antipsychotic prescribing remains common, despite serious risks. JAMA. 303:1582-1584.
85. Levine B, Jufer RA, Smialek JE (2000) Lamotrigine distribution in two postmortem cases. J Anal Toxicol. 24:635-637.
86. Link BG, Phelan JC, Bresnahan M, Stueve A, Pescosolido BA (1999) Public conceptions of mental illness: labels, causes, dangerousness, and social distance. Am J Public Health. 89:1328-1333.
87. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM (1994) The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 31:281-294.
88. Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer JC, Drab A, Benson BE (2001) 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 19:337-395.
89. Malhi GS, Adams D, Cahill CM, Dodd S, Berk M (2009) The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs. 69:2063-2101.
90. Manning JS, Haykal RF, Akiskal HS (1999) The role of bipolarity in depression in the family practice setting. Psychiatr Clin North Am. 22:689-703.
91. Manning JS, Haykal RF, Connor PD, Akiskal HS (1997) On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry. 38:102-108.
92. McHugh PR (1995) Witches, multiple personalities, and other psychiatric artifacts. Nat Med. 1:110-114.
93. McIntyre RS (2010) Aripiprazole for the maintenance treatment of bipolar I disorder: A review. Clin Ther. 32:S32-S38.
94. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 64:543-552.
95. Miyamoto S, Lieberman J, Fleischhacker W, Marder S (Eds) (2003) Antipsychotic drugs. Chichester, UK: John Wiley & Sons.
96. Narasimhan M, Bruce TO, Masand P (2007) Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 3:579-587.
97. North C, Yutzy S (2010) Goodwin and Guze's psychiatric diagnosis. New York, NY: Oxford University Press.
98. Ozminkowski RJ, Dunn RL, Goetzel RZ, Cantor RI, Murnane J, Harrison M (1999) A return on investment evaluation of the Citibank, NA, health management program. Am J Health Promot. 14:31-43.
99. Papakostas GI (2010) The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 71:e03.
100. Paris J (2008) Prescriptions for the mind. New York, NY: Oxford University Press.
101. Peele PB, Xu Y, Kupfer DJ (2003) Insurance expenditures on bipolar disorder: Clinical and parity implications. Am J Psychiatry. 160:1286-1290.
102. Peretti S, Judge R, Hindmarch I (2000) Safety and tolerability considerations: Tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 403:17-25.
103. Perugi G, Akiskal HS, Lattanzi L, Cecconi D, Mastrocinque C, Patronelli A, Vignoli S, Bemi E (1998) The high prevalence of 'soft' bipolar (II) features in atypical depression. Compr Psychiatry. 39:63-71.
104. Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, Wittchen HU (2005) Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 15:425-434.
105. Piper A, Merskey H (2004a) The persistence of folly: A critical examination of dissociative identity disorder. Part I. The excesses of an improbable concept. Can J Psychiatry. 49:592-600.
106. Piper A, Merskey H (2004b) The persistence of folly: Critical examination of dissociative identity disorder. Part II. The defence and decline of multiple personality or dissociative identity disorder. Canadian journal of psychiatry. Can J Psychiatry. 49:678-683.
107. Piver A, Yatham LN, Lam RW (2002) Bipolar spectrum disorders. New perspectives. Can Fam Physician. 48:896-904.
108. Pope HG Jr, Lipinski JF Jr (1978) Diagnosis in schizophrenia and manic-depressive illness: A reassessment of the specificity of 'schizophrenic' symptoms in the light of current research. Arch Gen Psychiatry. 35:811-828.
109. Post R, Weiss S (Eds) (1989) Kindling and manic-depressive illness. London: Wiley.
110. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 264:2511-2518.
111. Robins E, Guze SB (1970) Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 126:983-987.
112. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM (2002) Promotion of prescription drugs to consumers. N Engl J Med. 346:498-505.
113. Sachs GS (1996) Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol. 16:32S-47S.
114. Sachs GS, Guille C (1999) Weight gain associated with use of psychotropic medications. J Clin Psychiatry. 1999;60(suppl 21):16-19.
115. Salazar WH (1996) Management of depression in the outpatient office. Med Clin North Am. 80:431-455.
116. Sedler MJ (1983) Falret's discovery: the origin of the concept of bipolar affective illness. Am J Psychiatry. 140:1127-1133.
117. Sharpe VA (1997) Why 'do no harm'? Theor Med. 18:197-215.
118. Shi L, Thiebaud P, McCombs JS (2004) The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the feeforservices California Medicaid (Medi-Cal) program. J Affect Disord. 82:373-383.
119. Shou M (1963) Normothymics, 'mood-normalizers': Are lithium and imipramine drugs specific for affective disorders? Br J Psychiatry. 109:803-809.
120. Singerman B, Stoltzman RK, Robins LN, Helzer JE, Croughan JL (1981) Diagnostic concordance between DSM-III, Feighner, and RDC. J Clin Psychiatry. 42:422-426.
121. Smith CM (2005) Origin and uses of primum non nocereVabove all, do no harm! J Clin Pharmacol. 45:371-377.
122. Spitzer RL, Endicott J, Robins E (1975) Clinical criteria for psychiatric diagnosis and DSM-III. Am J Psychiatry. 132:1187-1192.
123. Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 35:773-782.
124. Stewart C, El-Mallakh RS (2007) Is bipolar disorder overdiagnosed among patients with substance abuse? Bipolar Disord. 9:646-648.
125. Stip E, Tourjman V (2010) Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 32:S3-S20.
126. Stokes PE, Holtz A (1997) Fluoxetine tenth anniversary update: the progress continues. Clin Ther. 19:1135-1250.
127. Stoltzman RK, Helzer JE, Robins LN, Croughan JL, Singerman B (1981) How does DSM-III differ from the systems on which it was built? J Clin Psychiatry. 42:411-421.
128. Struening EL, Perlick DA, Link BG, Hellman F, Herman D, Sirey JA (2001) Stigma as a barrier to recovery: The extent to which caregivers believe most people devalue consumers and their families. Psychiatr Serv. 52:1633-1638.
129. Swainston Harrison T, Perry CM (2004) Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs. 64:1715-1736.
130. Taylor D (2009) Psychopharmacology and adverse effects of antipsychotic longacting injections: a review. Br J Psychiatry Suppl. 52:S13-S19.
131. Ten Have M, Vollebergh W, Bijl R, Nolen WA (2002) Bipolar disorder in the general population in the Netherlands (prevalence, consequences and care utilisation): Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord. 68:203-213.
132. US Department of Health and Human Service (2011a) Available at: http://www.hhs.gov/news/press/2010pres/04/20100427a.html. Accessed on January 5, 2011.
133. US Department of Health and Human Service (2011b) Available at: http://www.stopmedicarefraud.gov/pfizerfactsheet.html.
134. Umbricht D, Kane JM (1996) Medical complications of new antipsychotic drugs. Schizophr Bull. 22:475-483.
135. Woodruff RA, Jr, Reich T, Croughan JL (1977) Strategies of patient management in the presence of diagnostic uncertainty. Compr Psychiatry. 18:443-448.
136. World Health Organization (1977) The international statistical classification of diseases, injuries, and causes of death. Geneva: WHO.
137. World Health Organization (1992) The ICD-10 classification of mental and behavioral disorders: clinical description and diagnostic guidelines. Geneva: WHO.
138. Yatham LN (2005) Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry. 66:13-17.
139. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord. 11:225-255.
140. Zimmerman M, Galione JN, Ruggero CJ, Chelminski I, Dalrymple K, Young D (2010a) Overdiagnosis of bipolar disorder and disability payments. J Nerv Ment Dis. 198:452-454.
141. Zimmerman M, Ruggero CJ, Chelminski I, Young D (2008) Is bipolar disorder overdiagnosed? J Clin Psychiatry. 69:935-940.
142. Zimmerman M, Ruggero CJ, Chelminski I, Young D (2010b) Psychiatric diagnoses in patients previously overdiagnosed with bipolar disorder. J Clin Psychiatry. 71:26-31.